Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 9;11(2):e1753.
doi: 10.1097/TXD.0000000000001753. eCollection 2025 Feb.

Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?

Ahmed Alnughmush  1   2   3 , Ayman Sayyed  1   2   4 , Mats Remberger  5 , Eshrak Al-Shaibani  1   2 , Carol Chen  2 , Caden Chiarello  2 , Ivan Pasic  1   2 , Igor Novitzky-Basso  1   2 , Arjun Datt Law  1   2 , Wilson Lam  1   2 , Dennis Dong Hwan Kim  1   2 , Armin Gerbitz  1   2 , Auro Viswabandya  1   2 , Rajat Kumar  1   2 , Fotios V Michelis  1   2 , Jonas Mattsson  1   2   6
Affiliations

Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?

Ahmed Alnughmush et al. Transplant Direct. .

Abstract

Background: Despite decades of post-allogeneic hematopoietic cell transplantation (HCT) growth factor utilization, its role remains undefined, leading to ongoing debates and research. The theoretical impacts of growth factors have been challenged in numerous studies.

Methods: In this retrospective cohort study conducted at the Princess Margaret Cancer Centre, we analyzed the clinical outcomes of 509 patients who underwent allogeneic HCT between May 1, 2019, and May 31, 2022. This study aimed to assess the impact of granulocyte colony-stimulating factor (G-CSF) administration posttransplantation on neutrophil and platelet engraftment, incidence of bloodstream infections (BSIs), graft-versus-host disease, engraftment syndrome (ES), and survival metrics including overall survival, nonrelapse mortality, and graft-versus-host disease-free/relapse-free survival.

Results: Our findings indicate that G-CSF administration expedited neutrophil engraftment (16 versus 18 d, P = 0.009) and was associated with a decreased incidence of BSI (9.4% versus 31.3%, P = 0.014). However, this benefit was counterbalanced by a significant delay in platelet engraftment (21 versus 17 d, P < 0.001). Multivariate logistic regression analysis identified mismatched donors (odds ratio, 1.72; 95% confidence interval, 1.03-2.88; P = 0.038) and the duration of G-CSF therapy (odds ratio, 1.04; 95% confidence interval, 1.00-1.09; P = 0.038) as independent predictors for the development of ES. Despite these hematological impacts, there was no observed advantage in overall survival, nonrelapse mortality, or graft-versus-host disease-free/relapse-free survival among patients who received G-CSF compared with those who did not.

Conclusions: Although G-CSF post-HCT expedited neutrophil engraftment and reduced BSI risk, it did not result in a survival advantage. The association with ES necessitates careful consideration.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Hematological recovery. A: Neutrophil engraftment, B: Platelet engraftment. ANC, absolute neutrophil count; PLT, platelet.
FIGURE 2.
FIGURE 2.
Day 30 incidence of bloodstream infection. A: G-CSF before May 2021 vs. no G-CSF before or after May 2021, B: G-CSF before May 2021 vs. no G-CSF before May 2021, C: G-CSF before May 2021 vs. no G-CSF after May 2021. BSI, bloodstream infection; G-CSF, granulocyte colony-stimulating factor; HCT, hematopoietic cell transplant.
FIGURE 3.
FIGURE 3.
Risk of ES and its effect on hematological recovery. A: Incidence engraftment syndrome and correlation with number of G-CSF days including only recipients of G-CSF, B: Effect of engraftment syndrome on platelet engraftment with and without G-CSF, C: Effect of engraftment syndrome on neutrophil engraftment with and without G-CSF. ES, engraftment syndrome; G-CSF, granulocyte colony-stimulating factor.
FIGURE 4.
FIGURE 4.
Overall survival and NRM. A: Overall survival, B: Non-relapse mortality. G-CSF, granulocyte colony-stimulating factor; HCT, hematopoietic cell transplant; NRM, nonrelapse mortality.
See this image and copyright information in PMC

References

    1. Ringdén OTH, Le Blanc K, Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. Exp Hematol. 2005;33:505–512. - PubMed
    1. Hägglund H Ringdén O Man SO¨, et al. . A prospective randomized trial of Filgrastim (r-MetHuG-CSF) given at different times after unrelated bone marrow transplantation. 1999;24:831–836. - PubMed
    1. Stinson TJ, Adams JR, Bishop MR, et al. . Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2000;26:663–666. - PubMed
    1. Bishop MR, Tarantolo SR, Geller RB, et al. . A randomized, double-blind trial of Filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 96:80–85. - PubMed
    1. Przepiorka D, Smith TL, Folloder J, et al. . Controlled trial of Filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood. 2001;97(11):3405-3410. - PubMed

LinkOut - more resources